PO67 | Pancreatic cancer in a 71-year-old severe hemophilia A patient with inhibitors and sustained zero bleeding during emicizumab prophylaxis
Background: The HAVEN 1 trial demonstrated the efficacy and safety of emicizumab prophylaxis in severe hemophilia A with inhibitors. However, the management of bleeding events and high-risk surgical procedures remains a clinical challenge. Case Report: In 2020, a 67-year-old man with severe hemop...
Сохранить в:
| Формат: | Artigo |
|---|---|
| Язык: | Inglês |
| Опубликовано: |
PAGEPress Publications
2025-10-01
|
| Серии: | Bleeding, Thrombosis and Vascular Biology |
| Предметы: | |
| Online-ссылка: | https://www.btvb.org/btvb/article/view/336 |
| Метки: |
Нет меток, Требуется 1-ая метка записи!
|